Literature DB >> 12189228

Effects of St. John's wort on irinotecan metabolism.

Ron H J Mathijssen1, Jaap Verweij, Peter de Bruijn, Walter J Loos, Alex Sparreboom.   

Abstract

St. John's wort (SJW), a widely used herbal product, has been implicated in drug interactions resulting from the induced expression of the cytochrome P450 CYP3A4 isoform. In this study, we determined the effect of SJW on the metabolism of irinotecan, a pro-drug of SN-38 and a known substrate for CYP3A4. Five cancer patients were treated with irinotecan (350 mg/m(2), intravenously) in the presence and absence of SJW (900 mg daily, orally for 18 days) in an unblinded, randomized crossover study design. The plasma levels of the active metabolite SN-38 decreased by 42% (95% confidence interval [CI] = 14% to 70%) following SJW cotreatment with 1.0 micro M x h (95% CI = 0.34 micro M x h to 1.7 micro M x h) versus 1.7 micro M x h (95% CI = 0.83 micro M x h to 2.6 micro M x h) (P =.033, two-sided paired Student's t test). Consequently, the degree of myelosuppression was substantially worse in the absence of SJW. These findings indicate that patients on irinotecan treatment should refrain from taking SJW because plasma levels of SN-38 were dramatically reduced, which may have a deleterious impact on treatment outcome.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12189228     DOI: 10.1093/jnci/94.16.1247

Source DB:  PubMed          Journal:  J Natl Cancer Inst        ISSN: 0027-8874            Impact factor:   13.506


  74 in total

Review 1.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 2.  [Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance].

Authors:  Matthias Unger
Journal:  Wien Med Wochenschr       Date:  2010-12

Review 3.  Pharmacokinetic Herb-Drug Interactions: Insight into Mechanisms and Consequences.

Authors:  Enoche F Oga; Shuichi Sekine; Yoshihisa Shitara; Toshiharu Horie
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-04       Impact factor: 2.441

Review 4.  Cancer treatment and pharmacogenetics of cytochrome P450 enzymes.

Authors:  Ron H N van Schaik
Journal:  Invest New Drugs       Date:  2005-12       Impact factor: 3.850

Review 5.  The effect of St John's wort extracts on CYP3A: a systematic review of prospective clinical trials.

Authors:  D L Whitten; S P Myers; J A Hawrelak; H Wohlmuth
Journal:  Br J Clin Pharmacol       Date:  2006-09-29       Impact factor: 4.335

Review 6.  Which botanicals or other unconventional anticancer agents should we take to clinical trial?

Authors:  Andrew J Vickers
Journal:  J Soc Integr Oncol       Date:  2007

7.  Cancer therapeutics revisited; novel drugs targeting cell signalling pathways, genome wide association studies and other trials and tribulations.

Authors:  Lionel D Lewis
Journal:  Br J Clin Pharmacol       Date:  2013-09       Impact factor: 4.335

Review 8.  Alterations of chemotherapeutic pharmacokinetic profiles by drug-drug interactions.

Authors:  Sridhar Mani; Mohammed Ghalib; Imran Chaudhary; Sanjay Goel
Journal:  Expert Opin Drug Metab Toxicol       Date:  2009-02       Impact factor: 4.481

9.  An assessment of the impact of herb-drug combinations used by cancer patients.

Authors:  Saud M Alsanad; Rachel L Howard; Elizabeth M Williamson
Journal:  BMC Complement Altern Med       Date:  2016-10-18       Impact factor: 3.659

10.  Effect of St John's wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects.

Authors:  Xuemin Jiang; Kenneth M Williams; Winston S Liauw; Alaina J Ammit; Basil D Roufogalis; Colin C Duke; Richard O Day; Andrew J McLachlan
Journal:  Br J Clin Pharmacol       Date:  2004-05       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.